INmune Bio announces results of additional interim analysis of Phase 2 trial

INmune Bio announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer’s Disease, AD, trial demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes, CDR-SB, the accepted endpoint for AD trials. Key Findings: Statistical Correlation: An independent review confirmed a highly significant correlation between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial. Reliability: The correlation of EMACC when measured during the screening process and again at the first study visit before treatment was found to be 0.93. Differentiation Capability: The difference in EMACC performance between patients with CDR global ratings of 0.5 and those rated 1.0 was very large, with an effect size of 0.87